FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:768-769 September 6, 2001 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The report by Ostrowsky et al. (May 10 issue)¹ provides evidence that active infection-control interventions can reduce or eliminate the transmission of vancomycin-resistant enterococci in health care facilities. One limitation of that study, as they point out, is the relatively small proportion of patients in acute health care facilities who participated in the study, which may have limited its ability to assess the true prevalence of vancomycin-resistant enterococci.

We recently experienced an outbreak of vancomycin-resistant enterococci in a 560-bed university teaching hospital. Vancomycin-resistant enterococci were first isolated from a clinical specimen in November 1998. A point-prevalence survey . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Sahm, D. F. (2002). Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release. Antimicrob. Agents Chemother. 46: 1989-1992 [Abstract] [Full Text]